Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totaling 133,590 shares, an increase of 2,380.8% from the December 31st total of 5,385 shares. Approximately 8.4% of the company’s stock are short sold. Based on an average trading volume of 2,064,105 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 2,064,105 shares, the days-to-cover ratio is currently 0.1 days. Approximately 8.4% of the company’s stock are short sold.

Cardio Diagnostics Stock Up 1.7%

Shares of Cardio Diagnostics stock opened at $1.84 on Wednesday. The company has a 50 day moving average price of $2.77 and a 200 day moving average price of $3.56. The firm has a market capitalization of $3.37 million, a P/E ratio of -0.49 and a beta of 2.94. Cardio Diagnostics has a 52 week low of $1.64 and a 52 week high of $20.55.

Cardio Diagnostics (NASDAQ:CDIO) last released its earnings results on Wednesday, November 12th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.80) by $0.82. The company had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.15 million. Cardio Diagnostics had a negative net margin of 39,674.18% and a negative return on equity of 67.51%. As a group, research analysts anticipate that Cardio Diagnostics will post -0.55 earnings per share for the current fiscal year.

Institutional Trading of Cardio Diagnostics

A hedge fund recently bought a new stake in Cardio Diagnostics stock. Citadel Advisors LLC purchased a new stake in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 19,520 shares of the company’s stock, valued at approximately $79,000. Citadel Advisors LLC owned about 1.07% of Cardio Diagnostics as of its most recent filing with the SEC. 8.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardio Diagnostics in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.